Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GNR-055 in Healthy Volunteers
NCT06475404Phase 1Completed
- Sponsor
- Generium
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of verenafusp alfa in mucopolysaccharidosis type II (3 arms), sponsored by Generium. Primary endpoint: Proportion of participants with Adverse Events at Day 28. Started Apr 2023; status: completed.
02
Drugs
verenafusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT06475404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475404.